The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
NeuroNOS Secures $2.0 Million in Funding for Innovative Autism Therapy
Mar 24, 2025•about 1 year ago
Contract Type
partnership
BostonBiotechnologyHealth CareBiopharma
Description
NeuroNOS has secured an initial $2 million in equity financing from private investors to accelerate the preclinical development of a small-molecule drug designed as an injectable or oral treatment for children with autism. The therapy aims to address the underlying biological mechanisms of ASD by regulating nitric oxide (NO) levels in the brain.
Company Information
Company
NeuroNOS
Location
Boston, Massachusetts, United States
About
NeuroNOS is a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer’s disease and brain cancers.
BostonBiotechnologyHealth CareBiopharma